Retrophin Inc. (NASDAQ:RTRX)’s share price shot up 3.2% on Friday . The company traded as high as $18.47 and last traded at $18.33, with a volume of 268,462 shares changing hands. The stock had previously closed at $17.77.

A number of brokerages recently weighed in on RTRX. JMP Securities reissued a “buy” rating on shares of Retrophin in a report on Saturday, July 9th. BMO Capital Markets reissued a “buy” rating on shares of Retrophin in a research note on Wednesday, May 4th. Zacks Investment Research raised Retrophin from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research note on Saturday, April 23rd. Finally, Leerink Swann reissued a “buy” rating and set a $27.00 target price on shares of Retrophin in a research note on Monday, June 27th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $23.60.

The stock has a market cap of $664.57 million and a P/E ratio of 9.43. The firm’s 50 day moving average is $17.91 and its 200-day moving average is $15.94.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.36. The company earned $29 million during the quarter, compared to the consensus estimate of $31 million. Retrophin’s revenue for the quarter was up 66.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.18) earnings per share. Equities research analysts predict that Retrophin Inc. will post $0.08 EPS for the current fiscal year.

In other news, EVP Alvin Shih sold 8,750 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $17.75, for a total value of $155,312.50. Following the completion of the sale, the executive vice president now directly owns 167,084 shares of the company’s stock, valued at approximately $2,965,741. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Several large investors recently bought and sold shares of the stock. California State Teachers Retirement System raised its stake in Retrophin by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 64,781 shares of the biopharmaceutical company’s stock valued at $1,250,000 after buying an additional 1,129 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in Retrophin by 1,449.5% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 91,421 shares of the biopharmaceutical company’s stock valued at $1,763,000 after buying an additional 85,521 shares during the last quarter. Tekla Capital Management LLC bought a new stake in Retrophin during the fourth quarter valued at about $6,365,000. Finally, Turner Investments L.P. raised its stake in Retrophin by 61.6% in the fourth quarter. Turner Investments L.P. now owns 384,760 shares of the biopharmaceutical company’s stock valued at $7,422,000 after buying an additional 146,720 shares during the last quarter.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.